Novel Rx
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results…
This year at #ACR24, emulation trials are being presented.Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized…
5 months ago
Phase 2 DBRCT of daxdilimab, an immunoglobulin-like transcript 7 to target plasmacytoid dendritic cells
No difference in primary outcome... but kiiiinda looks like something there?
I dislike Phase 2's; should go straight to Phase 3 if able
#ACR24 @rheumnow Abstr#1542 https://t.co/osDWDskfnA
5 months ago
Systematic review & meta-analysis by DrHChaudhary et al @DaoudAnsaam @mmagrey1
showed that males w/ axSpA who were treated with biologics had ⬆️ BASDAI150 response & likely w/ ASDAS low dse activity vs. females w/axSpA
Again, effect of gender differences
@RheumNow #ACR24 abs599 https://t.co/2DPYC8exES
5 months ago
Coming from somewhere where biosimilars are SOC for many years, I just find it wild how things are biosimilar wise in the US. Reflected by so many abstracts, including lots of oral presentations, essentially on showing biosimilars work. #ACR24 @RheumNow
Poster Hall